Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study

Gut

Volumn 42, Issue 1, 1998, Pages 42-46

  Bearcroft, C P ^a   Perrett, D ^b   Farthing, M J G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

5 hydroxytryptamine; Diarrhoea predominant irritable bowel syndrome; Postprandial

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; IRRITABLE COLON; POSTPRANDIAL STATE; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; TEST MEAL;

EID: 0031980886     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.42.1.42     Document Type: Article

References (44)

1. Vassallo M, Camilleri M, Phillips SF, et al. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102:102-8.
2. Gorard DA, Libby GW, Farthing MJG. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome. Gut 1994;35:203-10.
3. Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987;93:727-33.
4. Gomborone JE, Dewsnap PA, Libby GW, et al. Abnormal illness attitudes in patients with irritable bowel syndrome. J Psychosomatic Res 1995;39:227-30.
5. Palmer RL, Stonehill E, Crisp AH, et al. Psychological characteristics of patients with the irritable bowel syndrome. Postgrad Med J 1974;50:416-9.
6. Bertaccini G. Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastrointestinal tract in the rat. J Physiol (Lond) 1960;153:239-49.
7. Erspamer V, Testini A. Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 1959;11:618-23.
8. Da Prada M, Tranzer JP, Fleischer A. Storage of 5-hydroxytryptamine in human blood platelets. Experimentia 1972;28:1328-9.
9. Davidson HI, Pilot MA. Does endogenous neuronal 5-hydroxytryptamine influence canine intestinal motility [abstract]? J Physiol (Lond) 1986;376:49P.
10. Bulbring E, Crema A. Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex. Br J Pharmacol 1958;13:444-57.
11. Gorard DA, Libby GW, Farthing MJG. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994;35: 496-500.
12. Talley NJ, Phillips SF, Haddad A, et al. GR38032F (Ondansetron), a selective 5-HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Ser 1990;35:477-80.
13. Scolapio JS, Camilleri M, von der Ohe MR, Hanson RB. Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol 1995;30:562-7.
14. Beubler E, Bukhave K, Rask-Madsen J. Significance of calcium for the prostaglandin E2-mediated secretory response to 5-hydroxytryptamine in the small intestine. Gastroenterology 1986;90:1972-7.
15. Donowitz M, Asarkof K, Pike G. Calcium dependence of serotonin-induced changes in rabbit ileal electrolyte transport. J Clin Invest 1980;66:341-52.
16. Feldman JM. Carcinoid tumours and syndrome. Semin Oncol 1987;14:237-46.
17. Anderson JV, Coupe MO, Morris JA, et al. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. BMJ 1987; 294:1129.
18. Von der Ohe MR, Camilleri M, Kvols LK. A 5-HT, antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhoea. Gastroenterology 1994;106:1184-9.
19. Oddsson E, Rask- Madson J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978;13:409-16.
20. Martensson HG, Zinner MJ, Jaffe BM. Effects of intraluminal perfusion with serotonin on jejunal motility. Dig Dis Sci 1986;31:811-6.
21. Ahonen A, Kyusola K, Penttila O. Enterochromaffin cells and macrophages in ulcerative colitis and irritable colon. Ann Clin Res 1976;8:1-7.
22. Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-HT, receptor antagonist in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993;7:175-80.
23. Steadman CJ, Talley NJ, Phillips NS, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome: a pilot study. Mayo Clinic Proc 1992;67:732-8.
24. Blum I, Vered Y, Graff E, et al. The influence of meal composition on plasma serotonin and norepinephrine concentrations. Metabolism 1992;41:137-40.
25. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards a positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.
26. Bearcroft CP, Farthing MJG, Perrett D. Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and tryptophan in plasma and urine by HPLC with fluorimetric detection. Biomed Chromatography 1995;9:23-7.
27. Chaudhary NA, Truelove SC. The irritable colon syndrome: a study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962;31:307-22
28. Anderson GM, Feibel FC, Cohen DJ. Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and plasma ultrafiltrate. Life Sci 1987;40: 1063-70.
29. Artigas F, Sarrias MJ, Martínez E, Gelpi E. Serotonin in body fluids: characterisation of human plasmatic and cerebrospinal fluid pools by means of a new HPLC method. Life Sci 1985;37:441-7.
30. Flachaire E, Beney C, Berthier A, et al. Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection. Clin Chem 1900;36: 2117-20.
31. Badcock NR, Spence M, Stern LM. Blood serotonin levels in adults, autistic and nonautistic children with a comparison of different methodologies. Ann Clin Biochem 1987;24:625-34.
32. Barnes NM, Ge J, Jones WG, et al. Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. Br J Cancer 1990;62:862-4.
33. Tagari PC, Boullin DJ, Davies CL. Simplified determination of serotonin in plasma by liquid chromatography with electrochemical detection. Clin Chem 1984;30:131-5.
34. Matuchansky C, Launay J-M. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. Gastroenterology 1995; 108:743-51.
35. Beck O, Wallen NH, Broijersen A, et al. On the accurate determination of serotonin in human plasma. Biochem Biophys Res Commun 1993;196:260-6.
36. Kellum JM, Jaffe BM. Validation and application of a radioimmunoassay for serotonin. Gastroenterology 1976;70:516-22.
37. Anderson GM, Feibel FC, Wetlaufer LA, et al. Effect of a meal on human whole blood serotonin. Gastroenterology 1985;88:86-9.
38. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-6.
39. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992;66:198-203.
40. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993;33:691-7.
41. Andrews PLR, Rapeport W, Sanger G. Neuropharmacology of emesis induced by anticancer therapy. Trends Pharmacol Sci 1988;9:334-41.
42. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983;24:405-11.
43. Gore S, Gilmore IT, Haigh CG, et al. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist Aliment Pharmacol Ther 1990;4:139-44.
44. 1 receptor antagonists. In: Fozard JR, Saxena PR, eds. Serotonin: molecular biology, receptors and functional effects. Basel: Birkhauser Verlag, 1991:381-8.